杜皮鲁玛
特应性皮炎
医学
皮肤病科
临床实习
内科学
物理疗法
作者
Young‐Soo Lee,Myoung‐Eun Kim,Dong‐Ho Nahm
出处
期刊:Allergy, Asthma and Immunology Research
[The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Allergy and Respiratory Disease]
日期:2021-01-01
卷期号:13 (5): 733-733
被引量:33
标识
DOI:10.4168/aair.2021.13.5.733
摘要
PURPOSE: Dupilumab is recommended to be administered biweekly to treat adult patients with moderate-to-severe atopic dermatitis (AD). Real clinical practice data on the clinical efficacy of monthly dupilumab therapy are limited. We analyzed real clinical practice data on the clinical efficacy of monthly dupilumab therapy and predictive markers for favorable clinical responses to the therapy. METHODS: Medical records of 57 adult patients with moderate-to-severe AD who received dupilumab therapy every 4 weeks for 16 weeks were analyzed retrospectively. Eczema Area and Severity Index (EASI) were recorded at baseline and week 16. Clinical responses to monthly dupilumab therapy were defined as the proportion of patients with decreased EASI scores of at least 50% or 75% from baseline at week 16 (EASI-50 or EASI-75). Blood eosinophil counts and serum lactate dehydrogenase (LDH) levels were measured at baseline and week 16. RESULTS: = 0.013). CONCLUSIONS: Monthly dupilumab therapy was clinically effective in adult patients with moderate-to-severe AD in real clinical practice. Baseline blood eosinophil count and serum LDH level could be predictive markers for clinical response to dupilumab therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI